GSK PLC Sponsored ADR (NYSE:GSK) Receives $53.00 Consensus Target Price from Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $53.00.

Several equities research analysts have weighed in on GSK shares. Jefferies Financial Group raised GSK to a “strong-buy” rating in a research report on Friday, July 17th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings lowered shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Citigroup assumed coverage on shares of GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th.

Hedge Funds Weigh In On GSK

Several institutional investors have recently bought and sold shares of GSK. Brighton Jones LLC purchased a new stake in GSK during the fourth quarter worth $528,000. Dorsey Wright & Associates purchased a new position in shares of GSK in the 1st quarter valued at $2,522,000. Kahn Brothers Group Inc. purchased a new position in shares of GSK in the 2nd quarter valued at $8,305,000. Fisher Asset Management LLC raised its position in shares of GSK by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after acquiring an additional 968,370 shares in the last quarter. Finally, PFA Pension Forsikringsaktieselskab bought a new position in shares of GSK in the 4th quarter worth $6,385,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE:GSK opened at $50.45 on Monday. The firm has a market cap of $102.04 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 1.99 and a beta of 0.35. The firm’s 50 day simple moving average is $51.77 and its 200-day simple moving average is $53.28. GSK has a one year low of $39.17 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82.

GSK (NYSE:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.GSK’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts predict that GSK will post 4.8 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Friday, August 14th. GSK’s payout ratio is 55.63%.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK said Phase II results showed its mRNA flu vaccine generated stronger immune responses than currently approved standard- and high-dose flu vaccines, while demonstrating good tolerability. The data support moving into a pivotal Phase III trial and improve the program’s potential to compete in the seasonal influenza market. GSK to Advance mRNA Influenza Vaccine Into Phase III Development
• Positive Sentiment: The pivotal study is designed to evaluate the vaccine’s ability to target two influenza strains, a strategy GSK believes could improve protection compared with existing products. Advancement strengthens the company’s vaccine pipeline and supports its longer-term growth strategy in Specialty Medicines and infectious disease. GSK’s Pivotal Test for mRNA Flu Vaccine Aims to Show Two Targets Are Better Than One
• Positive Sentiment: Analyst coverage notes that GSK’s robust pipeline and Specialty Medicines growth could support long-term gains after the shares declined over the past six months. The latest vaccine progress provides a potential catalyst for renewed investor interest. GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
• Neutral Sentiment: Phase III advancement is an important development milestone, but it does not guarantee approval or commercial success. Investors will focus on the size, durability and safety of the vaccine’s benefit in the late-stage trial, as well as development costs and timing.
• Negative Sentiment: GSK faces competition from other mRNA vaccine developers, including Moderna, and must demonstrate that its candidate offers a meaningful advantage over established flu shots. Delays, disappointing Phase III results or regulatory setbacks could limit the program’s value.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.